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Editorial on the Research Topic
Update on the Immune Mechanisms Against Respiratory Pathogens
Respiratory infections pose a continuous threat to humans due to their easy dissemination via aerial
transmission. As a consequence, they are leading causes of mortality and morbidity worldwide.
Lower respiratory tract infections (LRTI) remained the deadliest communicable diseases causing
3 million deaths worldwide in 2016 (1). Similarly, although the number of tuberculosis (TB)
deaths tends to decrease, it is still among the top 10 causes of global mortality with a yearly
death burden of about 1.6 million (2). The growing emergence of bacterial antibiotic resistance
is a major global challenge for the coming years, and several major respiratory pathogens are
included in the WHO priority list of bacteria for which new antibiotics are urgently needed (3).
In terms of target population, children under the age of five are the most susceptible hosts to
a plethora of respiratory pathogens. The elderly, and immunocompromised respiratory patients
suffering from cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), bronchiectasis,
neutrophilic asthma, or silicosis are also highly targeted by respiratory pathogens, which often
accelerates the fatal progression of the underlying chronic disease. Accordingly, understanding
microbial pathogenicity and host immunity against respiratory infections is essential for the
rational development of new and more effective therapeutics.
This Research Topic provides an updated overview of both microbial factors and host immune
mechanisms determining either the control of lung infection or the development of lung disease by
key respiratory pathogens includingMycobacterium tuberculosis (Mtb), Streptococcus pneumoniae,
Haemophilus influenzae, Bordetella pertussis, Pseudomonas aeruginosa, influenza virus, human
metapneumovirus (hMPV), Aspergillus spp, and Pneumocystis spp. Pathogen virulence factors
and/or targets for immune recognition, host factors involved in pathogen recognition and immune
defense, specific roles of immune cell subsets, and promising prophylactic and/or therapeutic
strategies against respiratory infections have been addressed.
Regarding pathogen virulence factors, Hsieh et al., elucidated the role of Group A
Streptococcus (GAS) NAD-glycohydrolase in causing depletion of intracellular NAD+ storage
and impairment of autophagosome acidification, which in turn facilitates GAS authophagocytic
killing escape and replication inside human endothelial cells. Alcalde-Rico and co-authors
showed a relationship between antibiotic resistance and virulence in P. aeruginosa, of particular
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importance in the case of chronic infections, given that
overexpression of the MexCD-OprJ multidrug efflux pump
extrudes 4-hydroxy-2-heptylquinoline, the precursor of the
P. aeruginosa Quinolone Signal (PQS), leading to low PQS
intracellular levels and reduced production of quorum sensing
(QS) signal molecules, which then impairs the production of
QS-regulated virulence factors including elastase, protease IV,
pyocyanin, rhamnolipids, and bacterial swarming. Moreover,
Nieto et al., identified hemagglutinin HA S110L mutation as a
potent determinant of attenuation in a pandemic 2009 H1N1
influenza virus previously isolated from a fatal case patient which
also presents a highly pathogenic mutation in the polymerase
subunit PA D529N, thus indicating that combination of
mutations contributes to the final phenotype of such isolate. Also
from the viral perspective, Soto et al., revised current knowledge
on hMPV mechanisms of immune evasion contributing to poor
innate immune response and thereby affecting the adaptive
immunity. In particular, G protein inhibition of the IFN-I
type and viral replication, SH protein inhibition of the NF-κB
pathway, M2.1 protein association with pathogenesis and viral
replication, and M2.2 protein inhibition of cellular responses
dependent on mitochondrial antiviral signaling (MAVS) were
revised. Campillo-Navarro et al. studied the production of mast
cells extracellular traps (MCETs) upon cell contact with Mtb, and
found that heat-killed, but not alive, Mtb can induce DNA release
by mast cells, by using a mechanism likely related to increased
NADPH oxidase activity and concomitant hydrogen peroxide
production in such mast cells. This study also demonstrates
that Mtb catalase acts as a bacterial factor likely involved in
production of MCETs. Lastly, Arias and co-authors revised the
mode of action of the fungal secondary metabolite gliotoxin
(GT), a well-known virulence factor of the Aspergillus genus.
GT is the most abundant mycotoxin produced by A. fumigatus,
it causes cell death by killing cells in the spleen, thymus, or
lymph nodes, and also immunosuppression by, among others,
blocking macrophages inflammatory immune response by direct
killing, or by inhibiting NF-κB mediated signaling as well
as phagocytosis.
In terms of innate immune determinants against respiratory
pathogens, several aspects have been considered. Li et al., showed
that hMPV infection strongly suppresses basal- and vitamin D
induced cathelicidin antimicrobial peptide (CAMP) expression
in human macrophages, by a mechanism independent of vitamin
D or interferon, but mediated through repressing the expression
of the transcription factor C/EBPα. Likewise, Eijkelkamp et al.
analyzed the antimicrobial properties of arachidonic acid (AA), a
long chain polyunsaturated free fatty acid increased in the blood
of S. pneumoniae infected animals, and showed that AA exerts its
antimicrobial activity via insertion into the bacterial membrane,
resulting in alteredmembrane composition and increased fluidity
which, however, did not increase pneumococcal susceptibility
to antibiotic, oxidative, or metal ion stress. Also as part of the
airways innate humoral arm, Casals et al., revised the roles of
the collectin and galectin families, two types of endogenous
lectins. Surfactant protein A (SP-A) and D (SP-D) are collectins
secreted to the alveolar fluid by type II airway epithelial cells
and to the airway lumen by Club and submucosal cells. Such
collectins act by aggregating pathogens, which hinders their entry
into epithelial cells and facilitates their removal by a variety
of mechanisms such as mucociliary clearance or phagocytosis,
promoting bacterial trapping by neutrophil extracellular traps
(NETs), enhancing phagocytosis, or up-regulating expression
of cell-surface receptors involved in microbial recognition.
Conversely, galectins can function both inside and outside cells,
their expression is altered in respiratory infections, bind to
different respiratory pathogens (for example, Gal-3 bindsmycolic
acids of the mycobacterial cell wall and lipopolysaccharides
from Klebsiella pneumoniae, and P. aeruginosa), modulate
the immune response to infection, and present intracellular
activities of importance for pathogens occupying subcellular
compartments. Lastly, pathogen subversion of host factors has
also been considered. Based on the notion that S. pneumoniae
exploits neutrophil elastase (NE) leakage to subvert host
innate immune responses, Domon et al., revealed that NE
downregulates expression of multiple cytokines through cleavage
of Toll-like receptors and myeloid differentiation factor 2,
and cleaves inflammatory cytokines and chemokines. Moreover,
NE inhibition increases inflammation and enhances bacterial
clearance in a mouse model of pneumococcal pneumonia, thus
suggesting its therapeutic potential.
As mentioned above, numerous chronic disease patients
are often targeted by respiratory pathogens, likely accelerating
the progression of the underlying chronic disease. This is a
clinical problem of increasingly recognized interest, and major
chronic respiratory diseases need to be jointly taken care off
by respiratory physicians and specialists on infectious diseases.
In this context, decreased levels of surfactant phospholipids
reported in smokers and patients with COPD may indicate a
role for surfactant lipids in host protection against bacterial
infection. García-Fojeda et al. analyzed the effects of surfactant
phospholipids on the interplay between H. influenzae and
pneumocytes, showing that multilamellar vesicles, that constitute
the tensoactive material of the surfactant, bind the pathogen
preventing its self-aggregation and epithelial entry; differently,
the use of small unilamellar vesicles, which are generated
after inspiration/expiration cycles and are endocytosed by
pneumocytes for their degradation and/or recycling, block
bacterial cell invasion by inhibiting Akt phosphorylation and
Rac1 GTPase activation. Of note, in vivo administration of
the hydrophobic fraction of lung surfactant enhances bacterial
clearance, thus suggesting its therapeutic potential. Su et al.
reviewed the disease progression of COPD in the context of host
immune cross-talk with non-typeable H. influenzae (NTHi), a
bacterium with a critical role in COPD exacerbations. Features
of the host-pathogen interplay leading to NTHi colonization and
adaptation to the COPD patient lower airways environment have
been thoroughly revised, with special emphasis on the altered
expression and unresponsiveness of human TLRs to NTHi
lipoproteins and lipooligosaccharide, or cigarette smoke negative
effects in both the patients innate and adaptive immunity,
altogether eventually facilitating NTHi long-term infection. On
the other hand, Konecˇný et al., reviewed current knowledge about
the impact of Mtb infection on silicosis, and about silica and
Mtb co-exposure on the host immunity. Silicosis is a disease
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of the lower respiratory system with a frequent concomitant
infection, and the co-occurrence of silica exposure, silicosis and
TB has long been identified in populations exposed to silica-
containing dust. Innate and adaptive cellular immune responses
in silicosis and TB have been revised highlighting, among others,
that macrophages preloaded with silica particles exhibit a higher
number of Mtb phagocytic cells as well as higher rates of
Mtb phagocytosis.
Our collection also explores host factors involved in the
immune response against fungal and TB infections. Pneumocystis
fungi cause fatal pneumonia in immunocompromised
individuals. Moreover, although Pneumocystis pneumonia
has gradually decreased in HIV patients due to antiretroviral
therapy, it is responsible for increasing mortality in non-HIV
patients. Li et al. provide insights into the function of IL-9 during
Pneumocystis infection. By using a IL-9 deficient mouse, the
authors demonstrate reduced fungal burden in lungs as well as
stronger Th17 responses, compared to wild-type mice. Further
experiments confirmed that IL-9 deficiency resulted in enhanced
Th17 cell differentiation, and IL-17A neutralization resulted
in increased fungal burden in IL-9 deficient mice. Regarding
immunity against TB, Mpande et al. explored the presence of
stem cell memory T CD4+ cells (TSCM) in TB infected humans.
This T cell subset is absent in quantiferon (GFT)-negative
individuals, but displays measurable, and maintained levels
after QFT conversion, suggesting that primary Mtb infection
induces TSCM cells. Profiling of Mtb-induced TSCM cells indicate
higher levels of CCR5, CCR6, CXCR3, granzyme A, granzyme
K, and granulysin than those found in naïve CD4+ and TSCM
cells. Notably, Mtb-primed TSCM cells were also functional and
produced IL-2, IFN-γ, and TNF-α upon antigen stimulation.
Since a key feature of TSCM cells is the long-term maintenance
of their proliferative capacity without antigenic stimulation,
understanding their functional role is expected to have valuable
implications in TB vaccine development. Independently, Latorre
et al. explored the use of immune markers correlating with TB
latency or TB disease, as valuable tools for disease management.
Once enrolled two cohorts of active and latent TB patients,
expression of CD27, and CCR4 homing markers was studied
in blood CD4+ T cells. A higher diagnostic accuracy for active
TB was achieved for CD27 within IFN-γ+TNF-α+CD4+
T-cells in response to ESAT-6/CFP-10 stimulation, followed
by CD27 and CCR4 markers within IFN-γ+CD4+ T-cells in
response to purified protein derivative (PPD). In an independent
study, Jaisinghani et al. sought to investigate metabolic signals
leading to granulomatous inflammation in pulmonary TB,
and found an association between inflammatory response and
the presence of triglyceride (TG)-rich foamy macrophages in
necrotic granulomas. The absence of these foamy macrophages
in solid granulomas paved the way for downstream experiments
to demonstrate that in vitro infection of macrophages with
Mtb leads to increased TG production only under necrotic
conditions. Notably, the human enzyme diacylglycerol O-
acyltransferase (DGAT1) involved in TG synthesis appears to be
responsible of this phenomenon since DGAT1 silencing resulted
in suppressed expression of pro-inflammatory mediators.
Lastly, Lacoma et al. reviewed a panoply of host genetic factors
involved in respiratory tract infections, including ciliopathies
leading to impaired mucociliary clearance, as those leading
to cystic fibrosis, deficiency in alpha 1 antitrysin in some
COPD patients, or disorders in humoral immunity leading to
primary immunodeficiencies. In addition, single nucleotide
polymorphisms (SNPs) in TLR-2, TNF-α, IL-12, IFN-γ, and
their corresponding receptors are associated with increased
risk of developing TB, while mutations in ICAM-3 have been
linked with reduced risk of disease. Moreover, the link between
treatment with different biological response modifiers and the
increased risk of pneumonia, influenza, TB, Pneumocystis, and
fungal infections of the respiratory tract has been revised.
This Research Topic also explored conventional and
unconventional therapeutic interventions against respiratory
pathogens. Despite the availability of vaccines and antibiotics
against major players in respiratory infections, some pathogens
are reluctant to be prevented by an efficacious vaccine, and
the emergence of antibiotic resistance is an alarming threat.
Moreover, some respiratory pathogens are prone to form
biofilms that otherwise result in enhanced antibiotic resistance.
Vázquez et al. reviewed respiratory pathogens fighting based
on the use of phage lysins which specifically target susceptible
bacteria by hydrolysing bacterial peptidoglycan, and whose
major advantage is the fact that raising resistance seems to be
unlikely. This strategy might circumvent current problems in
infection treatment failure, further resulting more friendly with
the human microbiome than currently overused antibiotics.
Phage lysins are particularly active against Gram-positive
pathogens (S. pneumoniae, S. aureus, and S. pyogenes) and
mycobacteria, and some strategies are also being developed
against Gram-negative pathogens (P. aeruginosa, Acinetobacter
baumanii, and K. pneumoniae). In addition, Domenech et al.
reviewed the combined use of antibodies and antibiotics to
treat respiratory infections. Alteration of cell surface structures
driven by antibiotics might result in increased exposure of
bacterial antigens, which in turn may act as an alternative
strategy to overcome multidrug resistant pathogens. Previous
studies using a S. pneumoniae sepsis model demonstrated the
synergistic action of antibodies with β-lactams and macrolides.
Several antibodies are currently being tested in clinical trials
against ESKAPE pathogens (Enterococcus faecium, S. aureus, K.
pneumoniae,A. baumannii, P. aeruginosa, and Enterobacter spp.)
and might pave the way for future combinations with existing
antibiotics. Ramos-Sevillano et al. provided and update on the
natural immunity against S. pneumoniae focused on antibody-
and Th17-mediated immunity against specific pneumococcal
antigens. This manuscript reviewed existing data regarding the
impact of natural immunity during nasopharyngeal colonization,
pneumonia or septicaemia by S. pneumoniae. Mechanisms
involved in preventing infection seem to be dependent on the
infected anatomical site, with an emphasis on antibodies during
systemic infection and on Th17 CD4+ T cells for nasopharyngeal
infection, with pneumonia seemingly a combination of these
two. Increasing knowledge by collecting human data might
help to understand why some patient subpopulations are at
high risk of infection, or also aid to improve future vaccine
strategies. Closely related, Liao et al. tried to decipher the
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protective mechanism of the live-attenuated pneumococcal
vaccine SPY1. Intranasal administration of this vaccine to mice
resulted in increased IL-12p70, IL-4, IL-5, and IL-17A, decreased
the infection-associated inflammatory cytokine TNF-α, and in
increased production of TGF-β1 in lung and spleen homogenates
which is in turn related to up-regulation of Smad2/3 and down-
regulation of the negative regulator Smad7. SPY1-specific Tregs
are supposed to participate in protection by enhanced expression
of the immune modulators PD-1 and CTLA-4. Gupta and Nizet
exploited the notion of stabilizing the host Hypoxia-Inducible
Factor-1 alpha (HIF-1α) in mesenchymal stem cells (MSCs) as
a promising therapeutic approach against severe pneumonia.
The use of the selective small molecule AKB-4924 resulted in
longer half live of HIF-1α, reduced MSC death under cytotoxic
conditions, and enhanced antibacterial capacity of MSC. Further,
using a model of E. coli experimental pneumonia, these authors
demonstrated sustained protection against mortality in mice.
Regarding pertussis, Solans and Locht reviewed the key role
of the respiratory mucosal immunity in protection against B.
pertussis and exploited current knowledge to explain long-lasting
immunity of BPZE1, a live-attenuated vaccine under clinical
development. Upon infection, B. pertussis triggers production
of secretory IgA (sIgA) and cellular immune mechanisms
as tissue resident memory T (Trm) cells characterized by
CD4+, CD69+, and/or CD103+ that produce IFN-γ and/or
IL-17. Intranasal vaccination of mice with BPZE1 induced
both sIgA and CD4+CD69+CD103+ Trm cells in the nasal
mucosa, and these cells produced high levels of IL-17. These
mechanisms are tough to be responsible to protect against nasal
colonization with virulent B. pertussis. Also related to pertussis
vaccination strategies, Varney et al. compared current acellular
and whole-cell pertussis vaccines in terms of their ability to
profile the hematopoietic stem and progenitor cell (HSPC)
responses. Whole cell but not acellular pertussis vaccine resulted
in expansion of HSPCs and increased circulating white blood
cells. Upon infection, HSPCs from whole-cell vaccinated mice
showed a faster maturation into developing B cells. Moreover,
immunization with whole-cell pertussis vaccine resulted in
enrichment of interferon-induced genes within HSPCs. These
results might help to improve current acellular pertussis vaccines
in humans. In an independent study, Thofte et al. highlight
the elongation factor thermo-unstable (EF-Tu) from NTHi as
a novel target for bactericidal antibodies, demonstrating that
EF-Tu is surface exposed and identifying immunodominant
epitopes in this protein. Anti-EF-Tu IgG detected EF-Tu on
unencapsulated bacteria, considerably less EF-Tu was found
at the surface of encapsulated H. influenzae serotype b (Hib)
and S. pneumoniae (serotypes 3 and 4), and capsule removal
facilitated EF-Tu exposure. Of note, anti-NTHi EF-Tu IgG
antibodies promoted complement-dependent killing of this and
other uncapsulated bacteria. Regarding treatment of patients
with Ig deficiencies, Langereis et al. revised current regimes of
Ig replacement therapies. Treatment of agammaglobulinemia
patients includes Ig preparations that only contain IgG but
lack IgA and IgM. Consequently, deficiency in these latter
Ig results in lesser control of respiratory infection. Current
regimes enriched in IgA and IgG including fresh frozen plasma,
pentaglobin, trimodulin, IgAbulin, or purified IgA and IgM
linked to a secretory component were reviewed. Lastly, Kroesen
et al. used aspirin at low doses to ameliorate lung pathology in
a murine model of TB, putting forward the notion that low-dose
aspirin may be beneficial when combined with standard anti-TB
treatment due to its anti-inflammatory effect and enhanced
Th1-cell responses.
Finally, we want to express our gratitude to all the authors who
have contributed to this Research Topic and to the reviewers for
their timely and critical job. We hope that the reader will find this
Research Topic motivating and helpful. We invite you to read the
following articles and immerse yourself in the interesting world
of the molecular mechanisms of host-pathogen interplay at the
human airways.
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